Abstract
Given the compromised bone quality and altered healing environment, fracture non-union in osteoporotic bones presents a complex challenge in orthopedics. As global populations age, the incidence of osteoporotic fractures rises, leading to increased delayed healing and non-union cases. The pathophysiology underlying non-union in osteoporotic patients involves impaired bone regeneration, reduced osteoblast function, and poor vascularity. Traditional management strategies - ranging from pharmacological interventions like bisphosphonates and teriparatides to surgical approaches such as bone grafting and mechanical fixation - often yield limited success due to the weakened bone structure. Recent advances, however, have introduced novel therapies such as growth factors, stem cell applications, gene therapy, and bioactive scaffolds that offer more targeted and biologically driven solutions. Emerging technologies like three-dimensional printing and nanotechnology further contribute to customized treatment strategies that hold promise for improved outcomes. Diagnostic approaches have also evolved, integrating radiological assessments and biomarkers to identify patients at risk for non-union better. Despite these advancements, challenges remain, including the high costs, technical complexities, and the need for more robust clinical evidence. Future directions involve optimizing these innovative treatments, validating their effectiveness in more extensive clinical trials, and integrating personalized medicine approaches to cater to the individual needs of osteoporotic patients. Overall, integrating these emerging therapeutic strategies alongside traditional practices represents a significant shift towards more effective and personalized management of fracture non-union in osteoporotic bones.